Abstract
New therapies based on the targeting of signal pathways (such as VHL/HIF-1) common to most renal cell carcinomas (RCC), have greatly improved the outlook for sufferers of this disease. Given the growing reputation of many microRNAs (miRNAs) as both tumor suppressors and oncogenes, the measurement and manipulation of these small nucleotides in RCC patients may provide yet another valuable advance in renal cancer diagnosis and treatment. The present review summarizes the current literature on the role of microRNAs in RCC development and progression emphasizing the interaction of specific miRNAs with both oncogenic and tumor suppressor pathways of particular importance in renal cancer.
Keywords: c-MET, cancer, hypoxia-inducible factor (HIF), mammalian target of rapamycin (mTOR), miRNA, renal cell carcinoma, vascular endothelial growth factor (VEGF), Von Hippel-Lindau protein (VHL).
Graphical Abstract
MicroRNA
Title:MicroRNAs in Renal Cell Carcinoma
Volume: 4 Issue: 1
Author(s): Donald F. Sellitti and Sonia Q. Doi
Affiliation:
Keywords: c-MET, cancer, hypoxia-inducible factor (HIF), mammalian target of rapamycin (mTOR), miRNA, renal cell carcinoma, vascular endothelial growth factor (VEGF), Von Hippel-Lindau protein (VHL).
Abstract: New therapies based on the targeting of signal pathways (such as VHL/HIF-1) common to most renal cell carcinomas (RCC), have greatly improved the outlook for sufferers of this disease. Given the growing reputation of many microRNAs (miRNAs) as both tumor suppressors and oncogenes, the measurement and manipulation of these small nucleotides in RCC patients may provide yet another valuable advance in renal cancer diagnosis and treatment. The present review summarizes the current literature on the role of microRNAs in RCC development and progression emphasizing the interaction of specific miRNAs with both oncogenic and tumor suppressor pathways of particular importance in renal cancer.
Export Options
About this article
Cite this article as:
Sellitti F. Donald and Doi Q. Sonia, MicroRNAs in Renal Cell Carcinoma, MicroRNA 2015; 4 (1) . https://dx.doi.org/10.2174/2211536604666150713105247
DOI https://dx.doi.org/10.2174/2211536604666150713105247 |
Print ISSN 2211-5366 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5374 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cellular Pharmacology, Antineoplastic Activity and Low In Vivo Toxicity of a Carboxylato-Bridged Platinum(II) Complex bis(acetato)diammine-bis-μ-acetato diplatinum (II) Dihydrate
Medicinal Chemistry Differential Enhancement of T Helper Type 1 (Th1)/Th2 Cytokine Production by Natural Killer T Cells Through Negative Feedback Regulation with Cytokine-conditioned Dendritic Cells
Current Immunology Reviews (Discontinued) Down-Regulation of Angiogenic Inhibitors: A Potential Pathogenic Mechanism for Diabetic Complications
Current Diabetes Reviews A Computer - Aided Drug Designing for Pharmacological Inhibition of Mutant ALK for the Treatment of Non-small Cell Lung Cancer
Current Topics in Medicinal Chemistry Radionuclide Molecular Imaging Using Affibody Molecules
Current Pharmaceutical Biotechnology Application of Recombinant and Non-Recombinant Peptides in the Determination of Tumor Response to Cancer Therapy
Current Pharmaceutical Biotechnology Integrins: Novel Therapeutic Targets for Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Toll-Like Receptors: Cost or Benefit for Cancer?
Current Pharmaceutical Design Alternative Splicing: A Promising Target for Pharmaceutical Inhibition of Pathological Angiogenesis?
Current Pharmaceutical Design Nanotechnology and Radiopharmaceuticals: Diagnostic and Therapeutic Approaches
Current Drug Delivery Oral Factor Xa (FXa) Inhibitors for Treatment of Heparin-induced Thrombocytopenia (HIT)
Current Drug Therapy Lactoferrin: A Biologically Active Molecule for Bone Regeneration
Current Medicinal Chemistry CX3CL1/CX3CR1 Axis, as the Therapeutic Potential in Renal Diseases: Friend or Foe?
Current Gene Therapy Adhesion Molecules in Lung Cancer: Implications in the Pathogenesis and Management
Current Pharmaceutical Design Natural Products as a Source for Antileishmanial and Antitrypanosomal Agents
Combinatorial Chemistry & High Throughput Screening Enzyme-responsive Nanoparticles for Anticancer Drug Delivery
Current Nanoscience Natural and Synthetic Retinoids: Structural Bases and Biological Effects of Potential Clinical Relevance for the Prevention and Treatment of Infection-Driven Tumors
Anti-Infective Agents in Medicinal Chemistry Molecular Chaperone ORP150 in ER Stress–related Diseases
Current Pharmaceutical Design Protein Secretome Analysis of Evolving and Responding Tumor Ecosystems
Current Proteomics Synthesis and Evaluation of Cytotoxic Activity of Some Pyrroles and Fused Pyrroles
Anti-Cancer Agents in Medicinal Chemistry